Evidence map›Paper›PMID 37115362›Full record

ArticleDigestive diseases and sciences2023

Comparing Patient-Reported Outcomes Among Anti-TNF-Experienced Patients with Crohn's Disease Initiating Vedolizumab Versus Ustekinumab.

Michael D Kappelman, J D Lewis, X Zhang, F C Lin, L Weisbein, W Chen, J Burris, J E Dorand, L E Parlett, K Haynes and 4 more

Abstract read
PubMed Publisher
In one paragraph

Article in Digestive diseases and sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

14 authors at 6 institutions in 1 country.

Michael D KappelmanUniversity of North Carolina at Chapel Hill, Bioinformatics Building, 130 Mason Farm Rd., Campus Box 7229, Chapel Hill, NC, 27599-7555, USA. michael_kappelman@med.unc.edu.ORCID http://orcid.org/0000-0002-0469-6856
J D LewisUniversity of Pennsylvania Perelman School of Medicine, Philadelphia, PA, USA.
X ZhangUniversity of North Carolina at Chapel Hill, Bioinformatics Building, 130 Mason Farm Rd., Campus Box 7229, Chapel Hill, NC, 27599-7555, USA.
F C LinUniversity of North Carolina at Chapel Hill, Bioinformatics Building, 130 Mason Farm Rd., Campus Box 7229, Chapel Hill, NC, 27599-7555, USA.
L WeisbeinUniversity of North Carolina at Chapel Hill, Bioinformatics Building, 130 Mason Farm Rd., Campus Box 7229, Chapel Hill, NC, 27599-7555, USA.
W ChenUniversity of North Carolina at Chapel Hill, Bioinformatics Building, 130 Mason Farm Rd., Campus Box 7229, Chapel Hill, NC, 27599-7555, USA.
J BurrisYale School of Medicine, New Haven, CT, USA.
J E DorandCrohn's & Colitis Foundation, New York, NY, USA.
L E ParlettHealthcore, Wilmington, DE, USA.
K HaynesHealthcore, Wilmington, DE, USA.
V NairMedical Outcomes Management and the Practice Research Network (PRACNET), Sharon, MA, USA.
A F KaulMedical Outcomes Management and the Practice Research Network (PRACNET), Sharon, MA, USA.
A DobesCrohn's & Colitis Foundation, New York, NY, USA.
M D LongUniversity of North Carolina at Chapel Hill, Bioinformatics Building, 130 Mason Farm Rd., Campus Box 7229, Chapel Hill, NC, 27599-7555, USA.
University of North Carolina at Chapel Hill · USCrohn's and Colitis Foundation · USResearch Network (United States) · USWilmington University · USUniversity of Pennsylvania · USYale University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPrimary and secondary non-response to anti-tumor necrosis factor (TNF) therapy is common in patients with Crohn's disease (CD), yet limited research has compared the effectiveness of subsequent biological therapy.

objectiveWe sought to compare the effectiveness of vedolizumab and ustekinumab in anti-TNF-experienced patients with CD, focusing on patient-prioritized patient-reported outcomes (PROs).

methodsWe conducted a prospective, internet-based cohort study nested within IBD Partners. We identified anti-TNF-experienced patients initiating with CD vedolizumab or ustekinumab and analyzed PROs reported approximately 6 months later (minimum 4 months, maximum 10 months). Co-primary outcomes were Patient-Reported Outcome Measurement Information System (PROMIS) domains of Fatigue and Pain Interference. Secondary outcomes included patient-reported short Crohn's disease activity index (sCDAI), treatment persistence, and corticosteroid use. Inverse probability of treatment weighting (IPTW) was used to control for a number of potential confounders and incorporated into linear and logistic regression models for continuous and categorical outcomes, respectively.

resultsOverall, 141 vedolizumab and 219 ustekinumab initiators were included in our analysis. After adjustment, we found no differences between treatment groups in our primary outcomes of Pain Interference or Fatigue or the secondary outcome of sCDAI. However, vedolizumab was associated with lower treatment persistence (OR 0.4, 95% CI 0.2-0.6) and higher corticosteroid use at follow-up assessment (OR 1.7, 95% CI 1.1-2.6). DISCUSSION: Among anti-TNF experienced patients with CD, Pain Interference or Fatigue was not significantly different 4-10 months after starting ustekinumab or vedolizumab. However, reduced steroid use and increased persistence suggest superiority of ustekinumab for non-PRO outcomes.

Indexed as

Crohn DiseaseUstekinumabAdrenal Cortex HormonesAntibodies, Monoclonal, HumanizedCohort StudiesHumansProspective StudiesRetrospective StudiesTreatment OutcomeTumor Necrosis Factor InhibitorsAdrenal Cortex HormonesAntibodies, Monoclonal, HumanizedTumor Necrosis Factor InhibitorsUstekinumabvedolizumabComparative effectivenessCrohn’s diseasePatient-reported outcomesUstekinumabVedolizumab

Identifiers

PMID37115362
OpenAlexW4367313835

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.